(BUSINESS WIRE)--As part of a nationwide effort to help communities fight congestion, Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, is partnering with the Ohio Association of Police Athletic & Activities League (PAL) to join two rooms creating more space for the local mentorship program. The mentorship program faces literal congestion, because the facility currently only accommodates 23 students. The expanded room will help 5
Press Release Archive
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 26. To access the Webcast, visit our Web site at www.pfizer.com/annualmeeting and click on the “Annual Meeting of Shareholders Webcast” link. Information on accessing and pre-registering for the Webcast will be available at www.pfizer.com beginning April 23more...
"We’re thankful to have been selected as one of the winners of the Advil® Congestion Relief Project,"
(BUSINESS WIRE)--As part of a nationwide effort to help communities fight congestion,
Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, is
partnering with the Ohio Association of Police Athletic & Activities
League (PAL) to join two rooms creating more space for the local
(BUSINESS WIRE)--As part of a nationwide effort to help communities fight congestion, Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, is partnering with local organization, CURE, to refurbish a trolley to be used to safely shuttle area youth to and from afterschool activities. Prior to the addition of this trolley, the program couldn’t accommodate all interested students due to lack of space on its buses. This season, Advil®more...
(BUSINESS WIRE)--One in five adults over the age of 20 in the United States has high cholesterol1, which is a major risk factor for cardiovascular disease, including heart attack and stroke. Eighty-eight percent of Illinois residents have at least one risk factor for cardiovascular disease2. Pfizer and Walgreens are showing Chicagoans how easy and convenient it can be to shop for and prepare meals that are low in cholesterol and fat as well as snacks to supportmore...
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 1, 2012. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2012 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.commore...
(BUSINESS WIRE)--Pfizer Oncology will present data from a variety of preclinical and clinical studies of Pfizer’s early-stage compounds, including data from Pfizer’s investigational antibody-drug conjugate (ADC) portfolio and research evaluating several molecules targeting novel pathways that play a crucial role in basic cellular functions, at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, IL, from March 31-April 4
(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced additional analyses from the ARISTOTLE and AVERROES clinical trials will be presented at the American College of Cardiology’s 61st Annual Scientific Session, March 24-27, 2012, in Chicago. The two large Phase 3 clinical trials compared ELIQUIS® (apixaban), an investigational compound for the prevention of stroke or systemic embolism in patients withmore...
March 12, 2012 - Biocon And Pfizer Conclude Commercialization Agreement
(BUSINESS WIRE)--Biocon and Pfizer today announced the conclusion of their alliance to commercialize Biocon’s biosimilar versions of Insulin and Insulin analog products. The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently. Biocon and Pfizer are committed to ensuring continuity of patient care and will work together to effect a seamlessmore...
(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that data from a Phase 3 study of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years. These data, which are being presented today during the 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Iguacu Falls, Brazil,more...
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Barclays Capital 2012 Global Healthcare Conference on Tuesday, March 13, 2012 at 3:45 p.m. Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Barclays Capital 2012 Global Healthcare Conferencemore...
--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, President and General Manager, Specialty Care and Oncology, at the Cowen and Company 32nd Annual Healthcare Conference on Tuesday, March 6, 2012 at 10:00 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Cowen and Company 32nd Annual Healthcare Conference” linkmore...
February 27, 2012 - Pfizer Acquires Alacer Corp., a Leading Vitamin Supplements Company
"Today marks the beginning of an exciting new chapter for Alacer and the Emergen-C health and wellness brand. It is a unique opportunity to join one of the world’s top performing consumer health care businesses,"
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) issued the following statement in response to today’s discussion by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the use of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in adults 50 years of age and older. Pfizer believes Prevnar 13 should be recommended for all adults 50 years of age and oldermore...
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceutical (SSE Code: 600267), a leading pharmaceutical company in China, today signed a framework agreement, advancing their previously announced memorandum of understanding (MOU) to establish a joint venture to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets. The framework agreement builds upon the MOU, and is an important milestone in themore...
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tafamidis meglumine, the company’s investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). TTR-FAP is a rare, progressive and fatal neurodegenerative disease that affects approximately 8,000 patients worldwide.1,2,3 The European Commission
February 1, 2012 - Pfizer Issues Statement On Voluntary Recall
"If you are a woman in the United States who has used Lo-Ovral or Norgestrel pills over the last several months, please consult with your physician and begin using a non-hormonal barrier method immediately."
(BUSINESS WIRE)--Pfizer Inc. today issued the following statement regarding the voluntary recall of Lo/Ovral®-28 (norgestrel and ethinyl estradiol):
(BUSINESS WIRE)--Pfizer Inc. announced today that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic)for customers in the U.S. market. An investigation by Pfizer found that some blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence. The cause was identified andmore...
--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE):
"Many companies and organisations have worked for decades to fight these horrific diseases. But no one company or organisation can do it alone. Today, we pledge to work hand-in-hand to revolutionize the way we fight these diseases now and in the future."
Pages
Press release archive foot note
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stay on top of Pfizer breaking news: Get News Alerts by RSS. 
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
 |
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page. |
Current Stock Price
| . |
. . |
| %Change | . | 52 Wk. High | . |
| Day High | . | 52 Wk. Low | . |
| Day Low | . | Mkt. Cap(Bil) | . |
| Open | . | ||
| Prev Close | . | Symbol | . |
| Vol. | . | Exchange | . |
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.